JP2013512866A - アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン - Google Patents

アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン Download PDF

Info

Publication number
JP2013512866A
JP2013512866A JP2012541362A JP2012541362A JP2013512866A JP 2013512866 A JP2013512866 A JP 2013512866A JP 2012541362 A JP2012541362 A JP 2012541362A JP 2012541362 A JP2012541362 A JP 2012541362A JP 2013512866 A JP2013512866 A JP 2013512866A
Authority
JP
Japan
Prior art keywords
ferlin
protein
epitope
apicomplexer
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012541362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512866A5 (cg-RX-API-DMAC10.html
Inventor
ミュラー，アン−クリスティン
モラート，エーファ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universität Heidelberg
Original Assignee
Universität Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Heidelberg filed Critical Universität Heidelberg
Publication of JP2013512866A publication Critical patent/JP2013512866A/ja
Publication of JP2013512866A5 publication Critical patent/JP2013512866A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012541362A 2009-12-05 2010-12-06 アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン Pending JP2013512866A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26702609P 2009-12-05 2009-12-05
US61/267,026 2009-12-05
PCT/EP2010/007399 WO2011066995A1 (en) 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins

Publications (2)

Publication Number Publication Date
JP2013512866A true JP2013512866A (ja) 2013-04-18
JP2013512866A5 JP2013512866A5 (cg-RX-API-DMAC10.html) 2017-01-26

Family

ID=43499977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012541362A Pending JP2013512866A (ja) 2009-12-05 2010-12-06 アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン

Country Status (8)

Country Link
US (1) US8968750B2 (cg-RX-API-DMAC10.html)
EP (1) EP2507259B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013512866A (cg-RX-API-DMAC10.html)
CN (1) CN102781958B (cg-RX-API-DMAC10.html)
BR (1) BR112012013581A8 (cg-RX-API-DMAC10.html)
CA (1) CA2783107C (cg-RX-API-DMAC10.html)
MX (1) MX2012006458A (cg-RX-API-DMAC10.html)
WO (1) WO2011066995A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012076157A2 (en) 2010-12-06 2012-06-14 Ruprecht-Karls-Universität Heidelberg Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
EP2941269B1 (en) * 2013-01-07 2020-12-09 Mucosal Vaccine Technologies LLC Therapeutic vaccines for treating herpes simplex virus type 2 infections
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510877A (ja) * 1994-03-31 1997-11-04 アイシス・イノベーション・リミテッド マラリアペプチド
WO2004037856A2 (en) * 2002-10-25 2004-05-06 Institut Pasteur Plasmodium falciparum virulence factor var o
WO2004078099A2 (en) * 2003-03-03 2004-09-16 Pevion Biotech Ltd. Compositions and methods for the generation of protective immune response against malaria
WO2005063804A1 (en) * 2003-12-30 2005-07-14 Københavns Universitet Panum Compounds useful in the diagnosis and treatment of malaria
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5198334A (en) * 1989-07-21 1993-03-30 Terumo Corporation Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells
AU5931698A (en) * 1997-01-21 1998-08-07 New York University Universal t-cell epitopes for anti-malarial vaccines
US20030077653A1 (en) * 2000-04-20 2003-04-24 The University Of Georgia Research Foundation, Inc. Method for the identification of active site protease inactivators
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
US8206725B2 (en) * 2003-08-26 2012-06-26 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP
JP4834671B2 (ja) * 2005-09-29 2011-12-14 株式会社マルハニチロ水産 成人病の予防及び治療に有効な組成物
GB0601059D0 (en) * 2006-01-19 2006-03-01 Univ Durham Target
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
WO2012076157A2 (en) * 2010-12-06 2012-06-14 Ruprecht-Karls-Universität Heidelberg Malaria vaccines based on pre-erythrocytic antigens from p. falciparum

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510877A (ja) * 1994-03-31 1997-11-04 アイシス・イノベーション・リミテッド マラリアペプチド
WO2004037856A2 (en) * 2002-10-25 2004-05-06 Institut Pasteur Plasmodium falciparum virulence factor var o
WO2004078099A2 (en) * 2003-03-03 2004-09-16 Pevion Biotech Ltd. Compositions and methods for the generation of protective immune response against malaria
WO2005063804A1 (en) * 2003-12-30 2005-07-14 Københavns Universitet Panum Compounds useful in the diagnosis and treatment of malaria
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6015004114; Ｔｒｅｎｄｓ　ｉｎ　Ｐａｒａｓｉｔｏｌｏｇｙ ２４，　２, 2007, ｐ．７４-８４ *
JPN6015004117; Ｉｎｆｅｃｔｉｏｎ　ａｎｄ　Ｉｍｍｕｎｉｔｙ ７５，　１２, 2007, ｐ．５９４７-５９５５ *
JPN6015004120; Ｐｈｉｌ．　Ｔｒａｎｓ．　Ｒ．　Ｓｏｃ．　Ｌｏｎｄ．　Ｂ ３５７, 2002, ｐ．２５-３３ *
JPN6015004124; Ｓｃｉｅｎｃｅ ３０７, 2005, ｐ．８２-８６ *
JPN6015004127; Ｎａｔｕｒｅ ４１９, 2002, ｐ．４９８-５１１ *
JPN6015004130; Ｎａｔｕｒｅ ４１９, 2002, ｐ．５１２-５１９ *
JPN6015004136; Ｊｏｕｒｎａｌ　ｏｆ　ｔｈｅ　Ｎｅｕｒｏｌｏｇｉｃａｌ　Ｓｃｉｅｎｃｅｓ ２６０, 2007, ｐ．１１４-１２３ *
JPN6015004138; Ｔｒｅｎｄｓ　ｉｎ　Ｃｅｌｌ　Ｂｉｏｌｏｇｙ １４，　４, 2004, ｐ．２０６-２１３ *
JPN6015053142; ＮＣＢＩ［ｏｎｌｉｎｅ］，　Ａｃｃｅｓｓｉｏｎ　Ｎｏ．　ＸＭ＿００１３４８６６８，　＜ＵＲＬ：　ｈｔｔｐ：／／ｗｗｗ．ｎｃｂｉ．ｎｌｍ．ｎｉｈ．ｇｏｖ／ｎｕｃｃｏｒｅ／１２４８０９８６３？ｓａｔ＝１３ *
JPN7015000319; ＥＭＢＬ／ＧｅｎＢａｎｋ／ＤＤＢＪ　ｄａｔａｂａｓｅｓ , 200803 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン

Also Published As

Publication number Publication date
EP2507259B1 (en) 2016-08-24
CA2783107C (en) 2018-08-07
CA2783107A1 (en) 2011-06-09
WO2011066995A1 (en) 2011-06-09
BR112012013581A2 (pt) 2017-01-10
US8968750B2 (en) 2015-03-03
EP2507259A1 (en) 2012-10-10
CN102781958B (zh) 2017-07-11
US20120308598A1 (en) 2012-12-06
MX2012006458A (es) 2012-09-07
BR112012013581A8 (pt) 2017-12-26
CN102781958A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
Aly et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection
van Dijk et al. A central role for P48/45 in malaria parasite male gamete fertility
Silvie et al. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development
Sheehy et al. ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
Bhatia et al. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice
US20220111030A1 (en) Antigen specific multi epitope-based anti-infective vaccines
Haussig et al. Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites
Montagna et al. Antigen export during liver infection of the malaria parasite augments protective immunity
Alves-Silva et al. A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani nucleoside hydrolase (NH36) optimizes cross-protection against Leishmania amazonesis infection
Nico et al. Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains
EP2507259B1 (en) Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins
Nico et al. Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell–driven protective response
Devender et al. Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate in Leishmania donovani-infected BALB/c mice
de Menezes et al. Long lived liver-resident memory T cells of biased specificities for abundant sporozoite antigens drive malaria protection by radiation-attenuated sporozoite vaccination
US9314517B2 (en) Parasite vaccine
EP2648744B1 (en) Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
Dou et al. Novel constructs of tuberculosis gene vaccine and its immune effect on mice
JP5573679B2 (ja) マラリアワクチン組成物および細胞媒介免疫性を惹起する成分
Cao et al. Protective efficacy of Toxoplasma gondii bivalent MAG1 and SAG1 DNA vaccine against acute toxoplasmosis in BALB/c mice
Ono et al. Actively induced antigen-specific CD8+ T cells by epitope-bearing parasite pre-infection but not prime/boost virus vector vaccination could ameliorate the course of Plasmodium yoelii blood-stage infection
JP2006151813A (ja) 細胞内寄生病原体に対する遺伝子ワクチン
Bunkofske et al. Epitopes in the GPI attachment signal peptide of Trypanosoma cruzi mucin proteins generate robust but delayed and nonprotective CD8+ T cell responses
CN104736710A (zh) 来自恶性疟原虫的p47(pfs47)或来自间日疟原虫的p47(pvs47)作为疫苗或药物筛选靶标用于抑制人疟疾传播的用途
EP4129328A1 (en) Genetically modified plasmodium parasite expressing il-6 - use to raise an immune response in a host against malaria at the pre-erythrocytic stage of development of the parasite
JP5813854B2 (ja) 熱帯熱マラリア原虫抗原

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161003

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170131